OS | DFS | |||||
---|---|---|---|---|---|---|
HR | 95 % CI | p | HR | 95 % CI | p | |
Age >65 years | 5.12 | 2.34–11.9 | <0.001 | 1.37 | 0.80–2.33 | 0.241 |
Male | 1.87 | 0.89–4.31 | 0.100 | 1.18 | 0.70–2.04 | 0.538 |
Synchronous disease | 2.45 | 1.14–5.85 | 0.021 | 1.50 | 0.87–2.65 | 0.141 |
Conversion disease | 1.56 | 0.36–4.75 | 0.504 | 1.99 | 1.02–3.70 | 0.0435 |
Node-positive primary tumor | 1.43 | 0.67–2.99 | 0.342 | 1.30 | 0.77–2.26 | 0.333 |
Rectum | 0.83 | 0.37–1.74 | 0.897 | 1.11 | 0.71–1.92 | 0.709 |
Adjuvant chemotherapy | 0.78 | 0.36–1.61 | 0.506 | 0.90 | 0.50–1.53 | 0.693 |
No. of liver metastases ≥5 | 1.43 | 0.63–3.06 | 0.164 | 2.18 | 1.23–3.79 | 0.0076 |
Maximum tumor size >5 cm | 1.32 | 0.48–3.15 | 0.555 | 1.99 | 1.04–3.56 | 0.0375 |
CA19-9 ≥100 U/mL | 1.40 | 0.55–3.13 | 0.457 | 1.46 | 0.77–2.63 | 0.235 |
R1 resection | 1.07 | 0.51–2.17 | 0.853 | 1.15 | 0.68–1.96 | 0.597 |